Drofenine or drofenine hydrochloride

Dyrk1A-IN-5 (compound 5j) is a potent and selective DYRK1A inhibitor, with an IC 50 of 6 nM. Dyrk1A-IN-5 dose-dependently reduces the phosphorylation of Thr434 in SF3B1, with an IC 50 of 0.5 μM. Dyrk1A-IN-5 inhibits phosphorylation of tau at Thr212,

Product Describtion:DZD9008 is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR.

Product Describtion:DZD9008 is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR.

Product Describtion:DZD9008 is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR.

Product Describtion:DZD9008 is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR.

Product Describtion:DZD9008 is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR.

An inhibitor of &beta-catenin/Tcf-mediated transcription and an antagonist of ligand-dependent activation of PPAR&gamma and PPAR&delta blocks the recruitment of &beta-catenin and GRIP1 to PPAR&gamma and PPAR&delta selectively toxic to some

An inhibitor of &beta-catenin/Tcf-mediated transcription and an antagonist of ligand-dependent activation of PPAR&gamma and PPAR&delta blocks the recruitment of &beta-catenin and GRIP1 to PPAR&gamma and PPAR&delta selectively toxic to some

An inhibitor of &beta-catenin/Tcf-mediated transcription and an antagonist of ligand-dependent activation of PPAR&gamma and PPAR&delta blocks the recruitment of &beta-catenin and GRIP1 to PPAR&gamma and PPAR&delta selectively toxic to some

An inhibitor of &beta-catenin/Tcf-mediated transcription and an antagonist of ligand-dependent activation of PPAR&gamma and PPAR&delta blocks the recruitment of &beta-catenin and GRIP1 to PPAR&gamma and PPAR&delta selectively toxic to some

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.Form:Solid.